Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Endothelin-1 (1-31) (Human) TFA, a potent vasoconstrictor and hypertensive agent, originates from the chymase-mediated selective hydrolysis of big ET-1 [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Endothelin-1 (1-31) (Human) TFA, a potent vasoconstrictor and hypertensive agent, originates from the chymase-mediated selective hydrolysis of big ET-1 [1]. |
In vitro | Endothelin-1 (1-31) (Human) at concentrations ranging from 100 pM to 100 nM over a 24-hour period induces proliferation of human mesangial cells [2]. Additionally, Endothelin-1 (1-31) (Human) at a concentration of 100 nM triggers ERK activation in human mesangial cells within a timeframe of 0 to 10 minutes [2]. |
In vivo | ET-1 (1-31) (100 nM; single dose) TFA induces constriction of the mesenteric arteries in mice. This vasoconstriction is likely mediated by ET A receptors and may increase with age. Notable gender differences have been observed in the context of current chronic diabetes [1]. |
Molecular Weight | 3742.18 |
Formula | C164H237F3N38O49S5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Endothelin-1 (1-31) (Human) TFA MAPK ERK inhibitor inhibit